New therapeutic strategies in allergic diseases

被引：6

作者：

Romagnani, S ^{[1
]}

机构：

[1] Univ Florence, Sect Allergy Clin Immunol & Resp Dis, Dept Internal Med, I-50134 Florence, Italy

来源：

DRUGS OF TODAY | 2003年 / 39卷 / 11期

关键词：

D O I：

10.1358/dot.2003.39.11.799463

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

During the past 10 years, strong evidence has been provided to suggest that type 2 T herpes (Th2) responses to 'innocuous' environmental antigens (allergens) play a critical triggering role in the development of allergic disorders. The important role of Th2 cytokines, IL-4, IL-5, IL-9, IL-13, in accounting for most pathophysiological manifestations of atopic allergy has been largely clarified by a series of studies performed in both human diseases and experimental animal models of allergy and asthma.

引用

收藏

页码：849 / 865

页数：17

相关论文

共 102 条

[1] Role of interleukin 10 in specific immunotherapy [J].

Akdis, CA ;

Blesken, T ;

Akdis, M ;

Wüthrich, B ;

Blaser, K .

JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (01) :98-106

[2] Epitope-specific T cell tolerance to phospholipase A(2) in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro [J].

Akdis, CA ;

Akdis, M ;

Blesken, T ;

Wymann, D ;

Alkan, SS ;

Muller, U ;

Blaser, K .

JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (07) :1676-1683

[3] Role of IL-10 in allergen-specific immunotherapy and normal response to allergens [J].

Akdis, CA ;

Blaser, K .

MICROBES AND INFECTION, 2001, 3 (11) :891-898

[4] Phenotype, localization, and mechanism of suppression of CD4+CD25+ human thymocytes [J].

Annunziato, F ;

Cosmi, L ;

Liotta, F ;

Lazzeri, E ;

Manetti, R ;

Vanini, V ;

Romagnani, P ;

Maggi, E ;

Romagnani, S .

JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (03) :379-387

[5]

Annunziato F, 2001, J ALLERGY CLIN IMMUN, V108, P815

[6] Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment [J].

Bernstein, DI ;

Harrison, CJ ;

Tomai, MA ;

Miller, RL .

JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (06) :844-849

[7] THE EFFECTS OF NEBULIZED RECOMBINANT INTERFERON-GAMMA IN ASTHMATIC AIRWAYS [J].

BOGUNIEWICZ, M ;

MARTIN, RJ ;

MARTIN, D ;

GIBSON, U ;

CELNIKER, A ;

WILLIAMS, M ;

LEUNG, DYM .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1995, 95 (01) :133-135

[8] Interleukin-4 receptor in moderate atopic asthma - A phase I/II randomized, placebo-controlled trial [J].

Borish, LC ;

Nelson, HS ;

Lanz, MJ ;

Claussen, L ;

Whitmore, JB ;

Agosti, JM ;

Garrison, L .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (06) :1816-1823

[9]

Broide D, 1998, J IMMUNOL, V161, P7054

[10] The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-γ-producing cells [J].

Brugnolo, F ;

Sampognaro, S ;

Liotta, F ;

Cosmi, L ;

Annunziato, F ;

Manuelli, C ;

Campi, P ;

Maggi, E ;

Romagnani, S ;

Parronchi, P .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (02) :380-388

← 1 2 3 4 5 6 7 8 9 10 →